网站主页>>>研发精选>>>临床前CDMO研发筛选相关化合物
CDMO是Contract Development and Manufacturing Organization的缩写,即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药(特别是创新药)工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力,是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化:创新性合成路线设计、工艺参数优化. 2, 中试放大:实验室工艺向规模化生产的转化 3, 注册批生产:支持客户新药申报的验证批生产. 4, 商业化生产:药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测:2026年全球CDMO市场规模:预计达1,189亿美元 2033年全球CDMO市场规模:预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物,已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前,在多肽、ADC、CGT等新型药物赛道的驱动下,全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力,全球市占率有望持续提升,行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

示例图片

临床前CDMO研发化合物筛选

  • Camphor

    中文名称:(±)-樟脑(合成)
    CAS号:76-22-2
    分子式: C10H16O 分子量: 152.23
    产品形式: free base
    研发状态: Recruiting
    研发用途: Idiopathic Pulmonary Arterial Hypertension
    研究机构: Amsterdam UMC location VUmc
    研发日期: March 1 2023
    研发阶段: Phase 2
    Camphor (2-Bornanone, Bornan-2-one, 2-Camphanone, Formosa) is a bicyclic monoterpene ketone found widely in plants, especially cinnamomum camphora and used topically as a skin antipruritic and as an anti-infective agent.

  • Ipragliflozin (ASP1941)

    中文名称:伊格列净
    CAS号:761423-87-4
    分子式: C21H21FOS 分子量: 404.45
    产品形式: free base
    研发状态: Completed
    研发用途: Type 2 Diabetes Mellitus
    研究机构: Astellas Pharma Europe B.V.; Astellas Pharma Inc
    研发日期: May 11 2016
    研发阶段: Phase 3
    Ipragliflozin (ASP1941) is a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor with an IC50 value of 7.4 nM for hSGLT2 and a 254-fold selectivity versus SGLT1.

  • Solithromycin

    中文名称:索利霉素
    CAS号:760981-83-7
    分子式: C43H65FN6O10 分子量: 845.01
    产品形式: free base
    研发状态: Terminated
    研发用途: Pulmonary Disease Chronic Obstructive
    研究机构: Imperial College London; Melinta Therapeutics Inc.
    研发日期: Jul-15
    研发阶段: Phase 2
    Solithromycin (CEM-101, OP-1068), belonging to the well-known class of macrolide antibiotics that also includes azithromycin, is a potent bacterial protein synthesis inhibitor.

  • Enalapril Maleate

    中文名称:马来酸依那普利
    CAS号:76095-16-4
    分子式: C20H28N2O5.C4H4O4 分子量: 492.52
    产品形式: Maleate
    研发状态: Completed
    研发用途: Heart Failure With Reduced Ejection Fraction; Renal Insufficiency
    研究机构: Cairo University
    研发日期: February 1 2021
    研发阶段: Not Applicable
    Enalapril (MK-421) Maleate is an angiotensin-converting enzyme (ACE) inhibitor, used in the treatment of hypertension, diabetic nephropathy, and chronic heart failure.

  • β-Cyclodextrin

    中文名称:β-环糊精
    CAS号:7585-39-9
    分子式: C42H70O35 分子量: 1134.98
    产品形式: Free Base
    研发状态: Completed
    研发用途: COVID-19
    研究机构: Gilead Sciences
    研发日期: July 21 2020
    研发阶段: Phase 2 : Phase 3
    β-Cyclodextrin (β-CD, Beta-Cyclodextrin) is a cyclic derivative of starch prepared from partially hydrolyzed starch (maltodextrin) by an enzymatic process. β-Cyclodextrin can be used as complexing agents to increase aqueous solubility of poorly soluble drugs and to increase their bioavailability and stability.

  • Tanespimycin (17-AAG)

    中文名称:坦螺旋霉素
    CAS号:75747-14-7
    分子式: C31H43N3O8 分子量: 585.69
    产品形式: free base
    研发状态: Terminated
    研发用途: Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Waldenström Macroglobulinemia
    研究机构: National Cancer Institute (NCI)
    研发日期: Apr-05
    研发阶段: Phase 1
    Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 3.

  • 免费注册, 助力研发,生产, 销售.

    招募中心

    我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!

    即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.

    试运营阶段,所有广告业务5折优惠

    分类广告投放

    依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.

    客户展示

    示例图片
    优秀企业推荐
    ×

    通知